These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 7909786

  • 1. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
    Untch M, Sevin BU, Perras JP, Angioli R, Untch A, Hightower RD, Koechli O, Averette HE.
    Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
    [Abstract] [Full Text] [Related]

  • 2. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H, Untch M.
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [Abstract] [Full Text] [Related]

  • 3. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A.
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 6. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K, Kikuchi Y, Kudoh K, Hirata J, Kita T, Nagata I.
    Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
    [Abstract] [Full Text] [Related]

  • 7. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
    O'Meara AT, Sevin BU.
    Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
    [Abstract] [Full Text] [Related]

  • 8. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Lele SB, Marchetti DL, Baker TR, Blumenson LE.
    Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
    [Abstract] [Full Text] [Related]

  • 9. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
    Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M.
    Cancer Res; 1995 Nov 15; 55(22):5276-82. PubMed ID: 7585588
    [Abstract] [Full Text] [Related]

  • 10. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS.
    Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753
    [Abstract] [Full Text] [Related]

  • 11. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
    Xiao Y, Li JD, Shi HL, Liu JH, Feng YL, Li MD.
    Ai Zheng; 2007 Apr 15; 26(4):386-9. PubMed ID: 17430657
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxicity of paclitaxel in combination with cisplatin and a new Pt-mercaptopyridine complex.
    Ragazzi E, D'Ancona S, Berti E, Carrara M.
    Anticancer Res; 2002 Apr 15; 22(5):2783-8. PubMed ID: 12529997
    [Abstract] [Full Text] [Related]

  • 13. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
    Tian HM, Shi XY, Fu J, Chao DY, Zhang K, Wu LY, Wang JW, Zhang W.
    Zhonghua Zhong Liu Za Zhi; 2005 May 15; 27(5):296-8. PubMed ID: 15996325
    [Abstract] [Full Text] [Related]

  • 14. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
    Yamazaki S, Sekine I, Saijo N.
    Gan To Kagaku Ryoho; 1998 Mar 15; 25(4):605-15. PubMed ID: 9530372
    [Abstract] [Full Text] [Related]

  • 15. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Aug 15; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [Abstract] [Full Text] [Related]

  • 16. Potential use of the adenosine triphosphate cell viability assay in endometrial cancer.
    Tam KF, Ng TY, Tsang PC, Li CF, Ngan HY.
    J Soc Gynecol Investig; 2006 Oct 15; 13(7):518-22. PubMed ID: 16979354
    [Abstract] [Full Text] [Related]

  • 17. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Pöch G, Indefrei D, Mallmann P, Andreotti PE.
    Clin Cancer Res; 1997 Sep 15; 3(9):1527-33. PubMed ID: 9815839
    [Abstract] [Full Text] [Related]

  • 18. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin.
    Chen G, Zeller WJ.
    Anticancer Res; 1993 Sep 15; 13(1):219-23. PubMed ID: 8476216
    [Abstract] [Full Text] [Related]

  • 19. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.
    Gynecol Oncol; 2001 Jun 15; 81(3):380-90. PubMed ID: 11371126
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of new drugs and combinations in gynecologic tumors and cancer cell lines with the ATP-cell viability assay.
    Untch M, Sevin BU.
    Contrib Gynecol Obstet; 1994 Jun 15; 19():145-55. PubMed ID: 7995046
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.